Penumbra Inc.
PEN | NYSE
$320.13
+$1.18 (+0.37%)
Nov 2, 2026, 10:16 AM ET · Market open
Company Profile
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Key Executives
| Name | Position |
|---|---|
| Adam Elsesser | Co-Founder, Chairman & Chief Executive Officer |
| Maggie S. Yuen | Chief Financial Officer |
| Pankaj Tiwari | Executive Vice President & Chief Information Officer |
| Arani Bose | Co-Founder & Director |
| Ben Sorci | Executive Vice President of Operations |
| Ben Tompkins | Executive Vice President of Development & Compliance |
| Jason Richard Mills | Executive Vice President of Strategy |
| Jee Hamlyn-Harris | Investor Relations Officer |
| Johanna Roberts | Executive Vice President, General Counsel & Secretary |
| Lambert Shiu | Chief Accounting Officer |
| Shruthi Narayan | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 8-K | Current Report |
| May 29, 2026 | SD | Filing |
| May 21, 2026 | 4 | Filing |
| May 07, 2026 | 425 | Filing |
| May 07, 2026 | 8-K | Current Report |
Penumbra Inc.
| Country | United States |
| IPO Date | Sep 18, 2015 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 4,700 |
| CEO | Adam Elsesser |
Contact Details
One Penumbra Place Alameda,
California 94502 United States
Stock Details
| Ticker Symbol | PEN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321732 |
| CUSIP Number | 70975L107 |
| ISIN Number | US70975L1070 |
| SIC Code | 3841 |
Recent News
- 3 days ago / prnewswire.comPenumbra, Inc. Reports Third Quarter 2026 Financial Results
- 13 days ago / prnewswire.comPenumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
- 27 days ago / prnewswire.comNew STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
- 2 months ago / zacks.comReasons to Retain Penumbra Stock in Your Portfolio for Now
- 3 months ago / prnewswire.comPenumbra, Inc. Reports Second Quarter 2026 Financial Results
- 3 months ago / gurufocus.comTHUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
- 4 months ago / prnewswire.comFirst Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
- 5 months ago / zacks.comPenumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
- 5 months ago / prnewswire.comPenumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
- 5 months ago / prnewswire.comPenumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
Add to Watchlist
Select watchlists to add or remove PEN